Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Purchased by Aprio Wealth Management LLC

Aprio Wealth Management LLC boosted its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 14.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 3,055 shares of the company’s stock after acquiring an additional 380 shares during the quarter. Aprio Wealth Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $243,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of RDY. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Dr. Reddy’s Laboratories by 318.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after buying an additional 283,700 shares during the last quarter. Millennium Management LLC raised its position in Dr. Reddy’s Laboratories by 61.4% in the second quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after purchasing an additional 126,472 shares during the period. Schroder Investment Management Group raised its position in Dr. Reddy’s Laboratories by 77.6% in the fourth quarter. Schroder Investment Management Group now owns 266,653 shares of the company’s stock valued at $18,554,000 after purchasing an additional 116,488 shares during the period. Fisher Asset Management LLC increased its position in shares of Dr. Reddy’s Laboratories by 126.5% during the fourth quarter. Fisher Asset Management LLC now owns 205,280 shares of the company’s stock worth $14,283,000 after acquiring an additional 114,630 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Dr. Reddy’s Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after acquiring an additional 114,294 shares during the period. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 1.4 %

NYSE RDY opened at $78.75 on Wednesday. The stock has a market capitalization of $13.14 billion, a P/E ratio of 19.54, a P/E/G ratio of 1.75 and a beta of 0.55. Dr. Reddy’s Laboratories Limited has a 52-week low of $63.72 and a 52-week high of $84.46. The firm has a 50-day moving average price of $80.96 and a 200 day moving average price of $76.08. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%. The business had revenue of $919.80 million for the quarter, compared to analysts’ expectations of $861.68 million. Equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Barclays upped their price objective on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.